Logo image of STTK

SHATTUCK LABS INC (STTK) Stock Fundamental Analysis

USA - NASDAQ:STTK - US82024L1035 - Common Stock

2.2 USD
-0.19 (-7.95%)
Last: 10/9/2025, 4:30:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to STTK. STTK was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for STTK as it has an excellent financial health rating, but there are worries on the profitability. STTK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year STTK has reported negative net income.
In the past year STTK has reported a negative cash flow from operations.
STTK had negative earnings in each of the past 5 years.
In the past 5 years STTK always reported negative operating cash flow.
STTK Yearly Net Income VS EBIT VS OCF VS FCFSTTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

STTK has a Return On Assets of -95.56%. This is in the lower half of the industry: STTK underperforms 74.63% of its industry peers.
Looking at the Return On Equity, with a value of -107.88%, STTK is in line with its industry, outperforming 43.66% of the companies in the same industry.
Industry RankSector Rank
ROA -95.56%
ROE -107.88%
ROIC N/A
ROA(3y)-62.4%
ROA(5y)-42.55%
ROE(3y)-70.96%
ROE(5y)-48.25%
ROIC(3y)N/A
ROIC(5y)N/A
STTK Yearly ROA, ROE, ROICSTTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for STTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STTK Yearly Profit, Operating, Gross MarginsSTTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

STTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STTK has more shares outstanding
STTK has more shares outstanding than it did 5 years ago.
There is no outstanding debt for STTK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STTK Yearly Shares OutstandingSTTK Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
STTK Yearly Total Debt VS Total AssetsSTTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -1.89, we must say that STTK is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of STTK (-1.89) is comparable to the rest of the industry.
There is no outstanding debt for STTK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.89
ROIC/WACCN/A
WACC9.55%
STTK Yearly LT Debt VS Equity VS FCFSTTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 10.25 indicates that STTK has no problem at all paying its short term obligations.
STTK has a Current ratio of 10.25. This is amongst the best in the industry. STTK outperforms 81.53% of its industry peers.
A Quick Ratio of 10.25 indicates that STTK has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.25, STTK belongs to the best of the industry, outperforming 81.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.25
Quick Ratio 10.25
STTK Yearly Current Assets VS Current LiabilitesSTTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.59% over the past year.
The Revenue for STTK has decreased by -27.40% in the past year. This is quite bad
STTK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.37% yearly.
EPS 1Y (TTM)34.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-42.45%
Revenue growth 5Y-10.37%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, STTK will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.18% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y43.36%
EPS Next 2Y24.68%
EPS Next 3Y13.19%
EPS Next 5Y9.18%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
STTK Yearly Revenue VS EstimatesSTTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2031 100M 200M 300M 400M
STTK Yearly EPS VS EstimatesSTTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

STTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STTK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STTK Price Earnings VS Forward Price EarningsSTTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STTK Per share dataSTTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

STTK's earnings are expected to grow with 13.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.68%
EPS Next 3Y13.19%

More info and screens

0

5. Dividend

5.1 Amount

STTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SHATTUCK LABS INC

NASDAQ:STTK (10/9/2025, 4:30:00 PM)

2.2

-0.19 (-7.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners55.29%
Inst Owner Change0%
Ins Owners2.24%
Ins Owner Change0.02%
Market Cap105.38M
Analysts80
Price Target2.35 (6.82%)
Short Float %1.09%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.92%
Min EPS beat(2)3.96%
Max EPS beat(2)5.88%
EPS beat(4)3
Avg EPS beat(4)4.66%
Min EPS beat(4)-13.57%
Max EPS beat(4)22.37%
EPS beat(8)6
Avg EPS beat(8)5.55%
EPS beat(12)10
Avg EPS beat(12)7.91%
EPS beat(16)12
Avg EPS beat(16)14.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)57.99%
PT rev (3m)-6.23%
EPS NQ rev (1m)6.1%
EPS NQ rev (3m)42.26%
EPS NY rev (1m)9.77%
EPS NY rev (3m)19.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 35.16
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.85
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.06
BVpS1.19
TBVpS1.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.56%
ROE -107.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.4%
ROA(5y)-42.55%
ROE(3y)-70.96%
ROE(5y)-48.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.12%
Cap/Sales 1.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.25
Quick Ratio 10.25
Altman-Z -1.89
F-Score6
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)129.93%
Cap/Depr(5y)216.43%
Cap/Sales(3y)603.92%
Cap/Sales(5y)369.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y43.36%
EPS Next 2Y24.68%
EPS Next 3Y13.19%
EPS Next 5Y9.18%
Revenue 1Y (TTM)-27.4%
Revenue growth 3Y-42.45%
Revenue growth 5Y-10.37%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.5%
EBIT Next 3Y2.44%
EBIT Next 5Y-5.63%
FCF growth 1Y43.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.37%
OCF growth 3YN/A
OCF growth 5YN/A